Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study.

Klamroth, Robert; Windyga, Jerzy; Radulescu, Vlad; Collins, Peter W; Stasyshyn, Oleksandra; Ibrahim, Hishamshah Mohd; Engl, Werner; Tangada, Srilatha D; Savage, William; Ewenstein, Bruce

Klamroth, Robert; Windyga, Jerzy; Radulescu, Vlad; Collins, Peter W; Stasyshyn, Oleksandra; Ibrahim, Hishamshah Mohd; Engl, Werner; Tangada, Srilatha D; Savage, William; Ewenstein, Bruce.

Affiliation

Klamroth R; Department for Internal Medicine, Vascular Medicine and Haemostaseology, Vivantes Klinikum Friedrichshain, Berlin, Germany.
Windyga J; Department of Hemostasis Disorders and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Radulescu V; Hemophilia Treatment Center, University of Kentucky, Lexington, KY.
Collins PW; Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Stasyshyn O; Academy of Medical Sciences of Ukraine, Lviv, Ukraine.
Ibrahim HM; Pediatric Department, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.
Engl W; Baxalta Innovations GmbH, a Takeda company, Vienna, Austria; and.
Tangada SD; Baxalta US Inc, a Takeda company, Cambridge, MA.
Savage W; Baxalta US Inc, a Takeda company, Cambridge, MA.
Ewenstein B; Baxalta US Inc, a Takeda company, Cambridge, MA.

Blood ; 137(13): 1818-1827, 2021 04 01.

Article in En | MEDLINE | ID: mdl-33150384

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Factor VIII / Coagulants / Hemophilia A Type of study: Clinical_trials / Etiology_studies / Guideline / Observational_studies Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: Blood Year: 2021 Document type: Article Affiliation country: Alemania Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google